Cargando…

Genetic background and evolution of relapses in aggressive B-cell lymphomas

Relapses of aggressive B-cell lymphomas pose a higher risk to affected patients because of potential treatment resistance and usually rapid tumor growth. Recent advances, such as targeting Bruton tyrosine kinase, have provided promising results in small numbers of cases, but treatment for the majori...

Descripción completa

Detalles Bibliográficos
Autores principales:	Juskevicius, Darius, Dirnhofer, Stephan, Tzankov, Alexandar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566014/ https://www.ncbi.nlm.nih.gov/pubmed/28554945 http://dx.doi.org/10.3324/haematol.2016.151647

Ejemplares similares

Genomic Landscape of Hodgkin Lymphoma
por: Brune, Magdalena M., et al.
Publicado: (2021)

Mutational landscape of marginal zone B-cell lymphomas of various origin: organotypic alterations and diagnostic potential for assignment of organ origin
por: Vela, Visar, et al.
Publicado: (2021)

Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort
por: Juskevicius, Darius, et al.
Publicado: (2017)

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study
por: Tzankov, Alexandar, et al.
Publicado: (2015)

TIRAP p.R81C is a novel lymphoma risk variant which enhances cell proliferation via NF-κB mediated signaling in B-cells
por: Burkhard, Regula, et al.
Publicado: (2019)

Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas
por: Tzankov, Alexandar, et al.
Publicado: (2007)

Relapsed angioimmunoblastic T-cell lymphoma with acquired expression of CD20: a case report and review of the literature
por: Banz, Yara, et al.
Publicado: (2013)

High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations
por: Pillonel, V., et al.
Publicado: (2018)

Diagnostic and Prognostic Utility of PD-1 In B Cell Lymphomas
por: Muenst, S., et al.
Publicado: (2010)

Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis
por: Obermann, Ellen C, et al.
Publicado: (2005)

Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells
por: Menter, Thomas, et al.
Publicado: (2018)

H3K27m3 overexpression as a new, BCL2 independent diagnostic tool in follicular and cutaneous follicle center lymphomas
por: Brune, Magdalena M., et al.
Publicado: (2022)

Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study †
por: Genta, Sofia, et al.
Publicado: (2022)

Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas
por: Volpetti, Stefano, et al.
Publicado: (2014)

Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma
por: Borgerding, Andrea, et al.
Publicado: (2009)

Histological and immunohistochemical features of the spleen in persistent polyclonal B-cell lymphocytosis closely mimic splenic B-cell lymphoma
por: Sun, Ping, et al.
Publicado: (2012)

Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype
por: Vogelsberg, Antonio, et al.
Publicado: (2020)

Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma
por: Nijland, Marcel, et al.
Publicado: (2018)

Novel Therapies for Aggressive B-Cell Lymphoma
por: Foon, Kenneth A., et al.
Publicado: (2012)

Extrafollicular proliferation of B‐blasts: Morphologic correlate to Spikevax‐induced lymphadenopathy
por: Tzankov, Alexandar, et al.
Publicado: (2022)

The Role of Structural Extracellular Matrix Proteins in Urothelial Bladder Cancer (Review)
por: Brunner, Andrea, et al.
Publicado: (2007)

DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma
por: Schmid, Corina A., et al.
Publicado: (2015)

Aggressive B-Cell Lymphomas
por: Naresh, Kikkeri N., et al.
Publicado: (2012)

Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma: An Underrecognized Aggressive Lymphoma
por: Morgan, Elizabeth A., et al.
Publicado: (2012)

Histone deacetylase 1 plays a predominant pro-oncogenic role in Eμ-myc driven B cell lymphoma
por: Pillonel, Vincent, et al.
Publicado: (2016)

Microenvironment-Centred Dynamics in Aggressive B-Cell Lymphomas
por: Cacciatore, Matilde, et al.
Publicado: (2012)

Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance
por: Berendsen, Madeleine R., et al.
Publicado: (2020)

Tracking the Genetic Susceptibility Background of B-Cell Non-Hodgkin’s Lymphomas from Genome-Wide Association Studies
por: Hernández-Verdin, Isaias, et al.
Publicado: (2020)

Vascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid Malignancies
por: Medinger, Michael, et al.
Publicado: (2010)

Inhibitors of Bcl-2 and Bruton’s tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models
por: Bertram, Katrin, et al.
Publicado: (2021)

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
por: Jain, Michael D, et al.
Publicado: (2018)

Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma
por: Reutter, Katrin, et al.
Publicado: (2020)

Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma
por: Stirm, Kristin, et al.
Publicado: (2021)

Hodgkin's Lymphoma and Paraneoplastic Phenomena in the Central Nervous System: A Case Report and Review of the Literature
por: Vetter, Marcus, et al.
Publicado: (2011)

Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma
por: Makita, Shinichi, et al.
Publicado: (2022)

Management of relapsed-refractory diffuse large B cell lymphoma
por: Raut, Lalit S., et al.
Publicado: (2014)

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
por: Lee, Boram, et al.
Publicado: (2021)

Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
por: Profitós-Pelejà, Núria, et al.
Publicado: (2022)

Molecular classification of aggressive B-cell lymphoma
por: Bojarczuk, Kamil, et al.
Publicado: (2019)

Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies
por: Brune, Magdalena M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j1paecgfqnjnfn5o127jcq0nou